Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | KDR | P35968 | 6/20 | 0.45 |
| ▸ | TRPV1 | Q8NER1 | 6/20 | 0.43 |
| ▸ | NAMPT | P43490 | 1/20 | 0.41 |
| ▸ | FLT1 | P17948 | 4/20 | 0.40 |
| ▸ | PRKCI | P41743 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3932887 | 0.92 | KMT2A (0.48) | KMT2AKDRTRPV1NAMPTFLT1 | |
| SCHEMBL1941872 | 0.92 | KDR (0.52) | KMT2AKDRTRPV1 | |
| SCHEMBL3927552 | 0.89 | KMT2A (0.45) | KMT2AKDRTRPV1NAMPTFLT1 | |
| SCHEMBL1940229 | 0.88 | KDR (0.59) | KMT2AKDRPRKCI | |
| SCHEMBL3935938 | 0.87 | KMT2A (0.44) | KMT2AKDRTRPV1NAMPTFLT1 | |
| SCHEMBL3924135 | 0.86 | KMT2A (0.46) | KMT2AKDRTRPV1NAMPTFLT1 | |
| SCHEMBL1941141 | 0.85 | TDP1 (0.44) | KMT2AKDRTRPV1 | |
| SCHEMBL1940352 | 0.85 | KMT2A (0.48) | KMT2AKDRPRKCI | |
| SCHEMBL1940215 | 0.85 | KDR (0.54) | KMT2AKDRTRPV1NAMPTFLT1 | |
| SCHEMBL1940973 | 0.84 | KMT2A (0.45) | KMT2AKDRPRKCI |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1717229-B1 | NOVEL CYCLIC COMPOUND HAVING 4-PYRIDYLALKYLTHIO GROUP HAVING (UN)SUBSTITUTED AMINO INTRODUCED THEREIN | SANTEN PHARMACEUTICAL CO LTD (JP) | 2011-06-15 | — | — | EP | disclosed |
| US-7544703-B2 | Cyclic compound having 4-pyridylalkylthio group having substituted or unsubstituted amino group introduced therein | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2009-06-09 | — | — | US | disclosed |
| US-20070149574-A1 | Novel cyclic compound having 4-pyridylalkylthio group having substituted or unsubstituted amino group introduced therein | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2007-06-28 | — | — | US | disclosed |
| EP-1717229-A1 | NOVEL CYCLIC COMPOUND HAVING 4-PYRIDYLALKYLTHIO GROUP HAVING (UN)SUBSTITUTED AMINO INTRODUCED THEREIN | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2006-11-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070149574-A1 | Novel cyclic compound having 4-pyridylalkylthio group having substituted or unsubstituted amino group introduced therein | FLT4, FLT1, TIE1 | KMT2A 2966/4885KDR 12/4885TRPV1 2238/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.